1. Home
  2. JLS vs CMMB Comparison

JLS vs CMMB Comparison

Compare JLS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

HOLD

Current Price

$18.42

Market Cap

100.9M

Sector

Finance

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.76

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLS
CMMB
Founded
2009
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.9M
13.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JLS
CMMB
Price
$18.42
$1.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
26.6K
92.9K
Earning Date
01-01-0001
03-02-2026
Dividend Yield
9.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.48
$1.60
52 Week High
$17.97
$8.80

Technical Indicators

Market Signals
Indicator
JLS
CMMB
Relative Strength Index (RSI) 55.15 36.59
Support Level $18.06 $1.70
Resistance Level $18.25 $1.93
Average True Range (ATR) 0.11 0.17
MACD 0.04 0.03
Stochastic Oscillator 97.50 33.51

Price Performance

Historical Comparison
JLS
CMMB

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: